Frazier Life Sciences Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001892134

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q4 2025 · 40 positions · Total reported value $3.72B · Top-10 concentration 71.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 22.7% · 6 new · 1 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +20.6% · vs SPY +5.8% · Prev Value $3.89B — last quarter positions weighted by this quarter price moves · ranking

In its Q4 2025 13F filing, Frazier Life Sciences Management, L.P. disclosed 40 equity positions with a combined reported value of $3.72B. The filing implies a focused portfolio: its ten largest positions account for 71.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2025 were NAMS ($594.39M), MIRM ($536.75M), ARQT ($286.76M). By sector, the heaviest allocations are Health Care 94.7%, Materials 0.3%. Versus the prior quarter, allocation shifted toward Health Care (+9.2pp) and away from Other (-9.3pp).

Versus the prior quarter, Frazier Life Sciences Management, L.P. opened 6 new positions, trimmed 1 and fully exited 3, a turnover rate of 22.7% of positions. The portfolio's overlap with the prior quarter was 67% of names.

The largest new positions opened in Q4 2025 were RAPT ($33.31M), VOR ($33.27M), MNKD ($23.96M).

Of the 3 positions fully exited versus the prior quarter, the largest were VRNA ($361.10M), RARE ($29.59M), MREO ($19.45M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2025)

  • RAPT RAPT THERAPEUTICS INC · $33.31M
  • VOR VOR BIOPHARMA INC · $33.27M
  • MNKD MANNKIND CORP · $23.96M
  • XLO XILIO THERAPEUTICS INC · $3.79M
  • IBIO IBIO INC · $3.77M

Fully Exited (vs previous quarter)

  • VRNA VERONA PHARMA PLC · prev qtr: $361.10M
  • RARE ULTRAGENYX PHARMACEUTICAL IN · prev qtr: $29.59M
  • MREO MEREO BIOPHARMA GROUP FUNSPONSORED ADR 1 ADR REPS 5 ORD SHS · prev qtr: $19.45M
  • AKRO AKERO THERAPEUTICS INC · prev qtr: $17.41M
  • PCVX VAXCYTE INC · prev qtr: $17.09M
  • JBIO JADE BIOSCIENCES INC · prev qtr: $12.20M
  • ASMB ASSEMBLY BIOSCIENCES INC · prev qtr: $11.68M
  • ADVM ADVERUM BIOTECHNOLOGIES INC · prev qtr: $9.41M

Insider Transactions (Form 4)

Latest Frazier Life Sciences Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Frazier Life Sciences Management, L.P. is an SEC-registered 13F filer. As of Q2 2026 it reported 41 US equity positions with a combined value of $4.59B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 41 positions · $4.59B reported value (Q2 2026)
  • Top 10 holdings = 73.6% of reported value
  • Largest position: MIRM (MIRUM PHARMACEUTICALS INC) at 19.6%
  • Average position size: $112.00M

Sector Tilt

  • Health Care 99.8%
  • Materials 0.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 8 added, 1 reduced, 3 exited
  • 26 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 94.7%
Materials 0.3%
Other 5.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 16.94M $594.39M 15.96%
15.96%
Add
2 6.80M $536.75M 14.42%
14.42%
Hold
3 9.87M $286.76M 7.70%
7.70%
Hold
4 3.55M $271.20M 7.28%
7.28%
Reduce
5 6.65M $209.80M 5.63%
5.63%
Hold
6 12.47M $206.82M 5.55%
5.55%
Hold
7 4.57M $189.22M 5.08%
5.08%
Hold
8 10.26M $128.45M 3.45%
3.45%
Hold
9 488.46K $120.42M 3.23%
3.23%
Reduce
10 1.26M $100.06M 2.69%
2.69%
Reduce
11 22.73M $84.55M 2.27%
2.27%
Hold
12 5.04M $81.39M 2.19%
2.19%
Hold
13 722.40K $75.61M 2.03%
2.03%
Hold
14 983.12K $70.91M 1.91%
1.91%
Add
15 797.46K $63.52M 1.71%
1.71%
Reduce
16 3.15M $61.67M 1.66%
1.66%
Add
17 728.64K $59.66M 1.60%
1.60%
Reduce
18 9.86M $59.47M 1.60%
1.60%
Reduce
19 934.64K $59.39M 1.59%
1.59%
Add
20 378.30K $51.02M 1.37%
1.37%
Hold
21 4.42M $43.94M 1.18%
1.18%
Hold
22 1.28M $34.83M 0.94%
0.94%
Hold
23 1.30M $34.65M 0.93%
0.93%
Add
24 1.90M $33.56M 0.90%
0.90%
Add
25 983.33K $33.31M 0.90%
0.90%
New
26 2.54M $33.27M 0.89%
0.89%
New
27 133.33K $28.43M 0.76%
0.76%
Hold
28 5.10M $27.80M 0.75%
0.75%
Hold
29 4.22M $23.96M 0.64%
0.64%
New
30 2.29M $20.21M 0.54%
0.54%
Hold
31 700.65K $19.60M 0.53%
0.53%
Hold
32 2.63M $17.49M 0.47%
0.47%
Hold
33 384.78K $13.36M 0.36%
0.36%
Hold
34 500.33K $11.51M 0.31%
0.31%
Hold
35 241.59K $9.23M 0.25%
0.25%
Reduce
36 4.62M $9.20M 0.25%
0.25%
Hold
37 3.87M $5.30M 0.14%
0.14%
Hold
38 521.00K $4.89M 0.13%
0.13%
Reduce
39 5.92M $3.79M 0.10%
0.10%
New
40 1.95M $3.77M 0.10%
0.10%
New

FAQ

What did Frazier Life Sciences Management, L.P. buy in 2025-Q4?

In its 2025-Q4 13F filing, Frazier Life Sciences Management, L.P. reported 40 equity positions worth $3.72B in aggregate; its largest disclosed positions were NAMS ($594.39M), MIRM ($536.75M), ARQT ($286.76M).

How large is Frazier Life Sciences Management, L.P.'s portfolio?

Frazier Life Sciences Management, L.P. reported $3.72B of long equity holdings across 40 positions as of 2025-Q4. Top-10 holdings account for 71.0% of reported value.

What is Frazier Life Sciences Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/frazier-life-sciences-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →